CD274 and gastric cancer: Among the monoclonal antibodies targeting pro-grammed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1), nivolumab, avelumab, and pembrolizumab have been most studied in the 3-line treatment of gastric cancer [5, 6].